Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859801 · ClinicalTrials.gov registry record
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy
A clinical trial of Bone Cancer Metastatic, sponsored by Society of Interventional Oncology.
- Recruiting
- Registry status
- 120
- Enrollment target
- 6
- Study locations
NCT06859801 is a study of Bone Cancer Metastatic that is actively recruiting participants, run by Society of Interventional Oncology. The registered enrollment target is 120 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT06859801, a study of Bone Cancer Metastatic, is actively recruiting participants, sponsored by Society of Interventional Oncology.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DEVICE Percutaneous Ablation
Study Locations (6)
Georgia
- Emory University Hospital - Atlanta
- Northside Hospital - Atlanta
California
- University of California San Diego Moores Cancer Center - San Diego
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University - St Louis
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2027-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06859801
The ClinicalTrials.gov registry entry for NCT06859801 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Society of Interventional Oncology, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT06859801 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Georgia, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06859801 about?
NCT06859801 is a clinical study titled "A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy". The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).
What is the current status of trial NCT06859801?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-10-23. Estimated completion is 2027-07-31.
What conditions does trial NCT06859801 study?
This clinical trial studies the following conditions: Bone Cancer Metastatic.
What interventions are being tested in trial NCT06859801?
The interventions under investigation include: Radiation Therapy (RADIATION), Percutaneous Ablation (DEVICE).
Who is sponsoring clinical trial NCT06859801?
This trial is sponsored by Society of Interventional Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859801 being conducted?
This trial has 6 study locations across California, Georgia, Minnesota, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.